Therapeutic effect of the regimen containing Moxifloxacin in intensive phase for pulmonary tuberculosis patients
10.3760/cma.j.issn.1008-6706.2011.02.022
- VernacularTitle:含莫西沙星强化期抗结核方案用于初治肺结核的效果评价
- Author:
Wei JIA
- Publication Type:Journal Article
- Keywords:
Tuberculosis,pulmonary;
Moxifloxacin;
Drug therapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(2):190-191
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and safety of the regimen containing Moxifloxacin in intensive phase for pulmonary tuberculosis patients. Methods 88 cases with initial tuberculosis(each group of 44 cases) were studied in comparison in the same period. The treatment group contained isoniazid, rifampicin and moxifloxacin of antituberculosis regime and the control group contained isoniazid,rifampicin and pyrazineamide. Results After 2 months intensive phase anti-tubercular treatment ,the sputum negative conversion rates was 95.0% and control's was 94.4%(P ＞ 0.05); the absorb rate of lesions: the treatment group 77.3 % and the control group 79.5%; the liver damage rate: the treatment group and control group was 68.2% ,34.1% respectively(P ＜ 0.05). Conclusion Anti-tuberculosis intensive phase regimes containing moxifloxacin for tuberculosis treatment was safe and effective in initial treatment of pulmonary tuberculose.
